Bio‑Rad EVP Barry James Receives RSUs, Exercises Derivatives

What Happened
Barry James, EVP and President (LSG) of Bio‑Rad Laboratories (BIO), was granted 4,313 restricted stock units (RSUs) on 2026-09-04 and converted a portion of those RSUs into common shares on 2026-09-05 and 2026-09-06. He exercised/converted 1,027 shares on 9/05 and 1,056 shares on 9/06 (2,083 total). To cover tax withholding, 369 shares on 9/05 and 470 shares on 9/06 (839 shares total) were surrendered at a reported per-share value of $386.11, totaling $323,947. The exercise/conversion showed $0 exercise price, consistent with RSU vesting rather than option purchases.

Key Details

• Transaction dates: Grant/award 2026-09-04; conversions/exercises 2026-09-05 and 2026-09-06; filing date 2026-09-09.
• Specifics: 4,313 RSUs granted; 2,083 RSUs converted to shares (1,027 + 1,056); 839 shares withheld for taxes (369 + 470) at $386.11/share = $323,947 (combined).
• Transaction codes: A = Award/Grant (RSUs); M = Exercise/Conversion of derivative; F = Payment of exercise price or tax liability (share withholding).
• Footnotes: Each RSU represents a contingent right to one Class A share; RSUs vest over four years (25% after year one, remaining quarterly thereafter).
• Shares owned after transaction: Not disclosed in the provided excerpt of the Form 4.
• Timeliness: Filing occurred 2026-09-09 for transactions from 2026-09-04 to 2026-09-06. Form 4s are generally due within two business days of a transaction, so this filing appears later than the standard reporting window.

Context

• These entries reflect RSU vesting and conversion to shares, not an open‑market sale. The dispositions (F) are share withholdings to satisfy tax obligations—common and routine.
• The $0 exercise price and the footnotes confirm these were RSU-related conversions rather than purchases of options.
• No open-market purchases or sales were reported; therefore these transactions do not necessarily signal a bullish or bearish personal trade.